Search results
The meta-analyses including data from a total of 48 studies and >1800 patients revealed a significantly higher odds ratio for overall survival (OR (OS)) and disease-specific survival (OR (DSS)) in the non-NF1 group (OR (OS) = 1.75, 95% confidence interval [CI] = 1.28-2.39, and OR (DSS) = 1.68, 95% CI = 1.18-2.40).
- Survival outcomes of malignant peripheral nerve sheath tumors ...
Malignant peripheral nerve sheath tumors (MPNSTs) are...
- Malignant Peripheral Nerve Sheath Tumors—A Comprehensive ...
Although MPNST-specific results are not available at this...
- Survival outcomes of malignant peripheral nerve sheath tumors ...
Nov 15, 2012 · The meta-analyses including data from a total of 48 studies and >1800 patients revealed a significantly higher odds ratio for overall survival (OR OS) and disease-specific survival (OR DSS) in the non-NF1 group (OR OS = 1.75, 95% confidence interval [CI] = 1.28–2.39, and OR DSS = 1.68, 95% CI = 1.18–2.40).
- Matthias Kolberg, Maren Høland, Trude H. Ågesen, Helge R. Brekke, Knut Liestøl, Kirsten S. Hall, Fre...
- 10.1093/neuonc/nos287
- 2013
- Neuro Oncol. 2013 Feb; 15(2): 135-147.
Jan 9, 2024 · The prognosis for MPNST is poor and has remained abysmal in the last few decades with 5-year survival rates ranging between 16 and 62% [6, 7].
- 5-Year OS Rate, 5-Year EFS Rate, and LR Rate
- Prognostic Factors
- Sex
- Age
- NF 1 Status
- Tumor Size
- Tumor Depth
- Tumor Site
- Tumor Grade
- Metastases
The pooled data of 5-year OS rate consist of 22 studies [6, 11,12,13,14,15,16,17,18, 27, 28, 30,31,32, 34,35,36,37,38, 40, 42, 44] with 6742 patients. The 5-year OS rate was 49% (95%CI 45–53%). The pooled data of 5-year EFS rate consist of 8 studies [6, 11,12,13,14,15,16,17] with 1243 patients. The 5-year EFS rate was 37% (95%CI 32–43%). The pooled...
The prognostic factors with similar variables were pooled in the meta-analysis. The details of meta-analysis results are shown in Table 3 and Figure 2S.
Seven studies (including subgroups) [16, 29,30,31, 35] comparing the overall survival between male and female were included. Values of I2 = 55.3% and p = 0.037 were obtained after the HR values of OS were merged, indicating that heterogeneity existed. A random-effect model was used to merge the HR = 1.09, 95% CI 0.87–1.37 and p =0.466, suggesting t...
Nine studies (including subgroups) [14, 16, 29,30,31,32, 35, 37] compared the overall survival between the older and the younger subgroups. Values of I2 = 80.3% and p = 0.000 were obtained after the HR values of OS were merged, indicating that heterogeneity existed. A random-effect model was used to merge the HR = 1.45, 95% CI 0.98–2.16 and p =0.06...
A total of 13 studies [11, 13,14,15,16, 18, 30, 34,35,36,37, 40, 42] assessed the association between NF 1 and OS. Values of I2 = 34.1% and p = 0.110 were obtained after the HR values of OS were merged, indicating that heterogeneity did not exist. The pooled result via a fixed-effect model indicated that patients with NF 1-associated MPNST have poo...
For tumor size, the terms “large” and “small” are relative concept. For example, if the tumor size was divided into two sub-groups named “< 5 cm” and “≥ 5 cm,” the “large” represented “≥ 5 cm” and the “small” represented “< 5 cm.” Ten studies [13, 14, 17, 28, 30, 31, 35,36,37, 44] evaluated tumor size (the large vs. the small) as a risk factor for ...
Five studies [14, 15, 30, 35, 40] evaluated relation between tumor depth related to fascia and OS. Values of I2-= 0.00% and p = 0.744 were obtained after the HR values of OS were merged, indicating that heterogeneity did not exist and a fixed-effect model was applied. Collectively, deep to fascia versus superficial to fascia significantly increased...
A total of 6 studies [14,15,16, 18, 30, 40] evaluated the relation between the tumor site and OS. Five studies [15, 17, 18, 30, 40] compared the OS between trunk and extremity, with heterogeneity existing (I2 = 74.9% and p = 0.003) and a random-effect model applied. Trunk versus extremity had an increasing risk of bad prognosis (HR 1.79, 95% CI 1.0...
A total of 6 studies (including subgroups) [13,14,15,16, 31] assessed the association between the tumor grade and OS. Most of the studies [14, 16, 31] used AJCC 8 Stage (The American Joint Committee on Cancer released updated cancer staging in 2017—known as AJCC 8) to define tumor grade. Six studies (including subgroups) [13,14,15,16, 31] compared ...
There were 6 studies (including subgroups) [13, 16, 31, 32, 44] exploring OS and metastases included, with heterogeneity existing (I2 = 62.3% and p = 0.021) and a random-effect model applied. Patients with metastasis had poorer OS than those without (HR 2.30, 95% CI 1.50–3.51, p =0.000).
- Zhenyu Cai, Xiaodong Tang, Haijie Liang, Rongli Yang, Taiqiang Yan, Wei Guo
- 2020
Jan 9, 2024 · Malignant peripheral nerve sheath tumors (MPNSTs) are malignancies that demonstrate nerve sheath differentiation in the peripheral nervous system. They can occur sporadically or be associated with neurofibromatosis type 1 (NF1), an autosomal dominant neurocutaneous disorder, with up to 13% of patients developing MPNSTs in their lifetimes.
- 10.1186/s12957-023-03296-z
- 2024
- World J Surg Oncol. 2024; 22: 14.
Jan 1, 2022 · Although MPNST-specific results are not available at this time, general outcomes are compared favorably to prior studies. At a median follow-up time of 6.5 years, that study’s 5-year overall survival (OS) and event-free survival (EFS) were as follows—low risk: 96.2% and 88.9%, respectively.
People also ask
Are there survival meta-analyses for malignant peripheral nerve sheath tumors?
Do malignant peripheral nerve sheath tumor patients with neurofibromatosis type 1 have worse prognosis?
What is a malignant peripheral nerve sheath tumor (MPNST)?
Feb 12, 2021 · The prognosis of recurrent malignant peripheral nerve sheath tumors (MPNST) is dismal, with surgical resection being the only definitive salvage therapy. Treatment with chemoradiation...
